What smart money is saying about Pfizer Inc.
1 fund in our archive has pitched Pfizer Inc. — most recently Argent Capital Management Dividend Select Strategy in September 2026.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Get an email when a fund buys, sells or pitches it
Position history
Between Q2 2026 and Q3 2026, 4 fund letters reported a position in Pfizer Inc., with 1 buy (opened or added).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 3 | 1 | 0 | 1 |
| Q2 2026 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 4 positions · 1 move
- HoldsNexus Investment Management ULCSeptember 2026
“Microsoft and Meta Platforms led the way, along with our healthcare holdings Thermo Fisher, Gilead and Pfizer.”
Pfizer Inc. - September 2026
“In healthcare, we initiated a position in Pfizer, one of the world’s largest pharmaceutical companies, attracted by durable cash generation, a dividend yield above 6% that management has identified as its first capital allocation priority, improving cost discipline, and potential upside from a broad research pipeline.”
Pfizer Inc. - September 2026
“Our top contributors for the quarter4 were Pfizer, Merck, Ameriprise Financial, Danaher, and Prudential Financial.”
Pfizer Inc. - June 2026
“Our top detractors for the quarter were Hershey, Pfizer, McDonald’s, RTX and Allegion.”
Pfizer Inc.
Also mentioned · 2
These funds discuss Pfizer Inc. — as a competitor, benchmark or comparable — without disclosing a position in it.
- September 2026
“Zoetis (ZTS) Zoetis is a pet pharmaceutical company. Pfizer spun it off in 2013.”
Pfizer Inc. - June 2026
“Biologics have been coming into vogue over the last couple of decades, and so many of McKesson’s largest opportunities are in this category. As the name implies, biologics are derived from living organisms rather than static formulas of chemicals. These typically require more delicate storage and handling, for example, Pfizer states their COVID-19 vaccine is required to be stored between -90°C and -60°C.”
Pfizer Inc.
Fund coverage · 1 thesis
- Argent Capital Management Dividend Select StrategySeptember 2026
Pfizer offers a high dividend, low valuation, strong cash generation, and pipeline-driven upside supported by cost savings and oncology assets.
Read the full thesis
Read every full thesis on Pfizer Inc.
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→